Print

AVEG 009

A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination with IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) March 20, 1992
MN rgp120 Env gp120 B
MN rgp120 Protein
USA 57
NCT00001021
https://clinicaltrials.gov/show/NCT00001021